These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 34146720)

  • 1. MS-Based HLA-II Peptidomics Combined With Multiomics Will Aid the Development of Future Immunotherapies.
    Taylor HB; Klaeger S; Clauser KR; Sarkizova S; Weingarten-Gabbay S; Graham DB; Carr SA; Abelin JG
    Mol Cell Proteomics; 2021; 20():100116. PubMed ID: 34146720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Major histocompatibility complex class II+ invariant chain negative breast cancer cells present unique peptides that activate tumor-specific T cells from breast cancer patients.
    Chornoguz O; Gapeev A; O'Neill MC; Ostrand-Rosenberg S
    Mol Cell Proteomics; 2012 Nov; 11(11):1457-67. PubMed ID: 22942358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The CLIP-substituted invariant chain efficiently targets an antigenic peptide to HLA class II pathway in L cells.
    Fujii S; Senju S; Chen YZ; Ando M; Matsushita S; Nishimura Y
    Hum Immunol; 1998 Oct; 59(10):607-14. PubMed ID: 9757942
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mapping the HLA ligandome landscape of acute myeloid leukemia: a targeted approach toward peptide-based immunotherapy.
    Berlin C; Kowalewski DJ; Schuster H; Mirza N; Walz S; Handel M; Schmid-Horch B; Salih HR; Kanz L; Rammensee HG; Stevanović S; Stickel JS
    Leukemia; 2015 Mar; 29(3):647-59. PubMed ID: 25092142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Human Immunopeptidome Project: A Roadmap to Predict and Treat Immune Diseases.
    Vizcaíno JA; Kubiniok P; Kovalchik KA; Ma Q; Duquette JD; Mongrain I; Deutsch EW; Peters B; Sette A; Sirois I; Caron E
    Mol Cell Proteomics; 2020 Jan; 19(1):31-49. PubMed ID: 31744855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Challenges and opportunities in analyzing and modeling peptide presentation by HLA-II proteins.
    ElAbd H; Bacher P; Tholey A; Lenz TL; Franke A
    Front Immunol; 2023; 14():1107266. PubMed ID: 37063883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deciphering the HLA-E immunopeptidome with mass spectrometry: an opportunity for universal mRNA vaccines and T-cell-directed immunotherapies.
    Weitzen M; Shahbazy M; Kapoor S; Caron E
    Front Immunol; 2024; 15():1442783. PubMed ID: 39301027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantification of HLA-DM-Dependent Major Histocompatibility Complex of Class II Immunopeptidomes by the Peptide Landscape Antigenic Epitope Alignment Utility.
    Álvaro-Benito M; Morrison E; Abualrous ET; Kuropka B; Freund C
    Front Immunol; 2018; 9():872. PubMed ID: 29774024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heat shock protein 90-mediated peptide-selective presentation of cytosolic tumor antigen for direct recognition of tumors by CD4(+) T cells.
    Tsuji T; Matsuzaki J; Caballero OL; Jungbluth AA; Ritter G; Odunsi K; Old LJ; Gnjatic S
    J Immunol; 2012 Apr; 188(8):3851-8. PubMed ID: 22427632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Defining HLA-II Ligand Processing and Binding Rules with Mass Spectrometry Enhances Cancer Epitope Prediction.
    Abelin JG; Harjanto D; Malloy M; Suri P; Colson T; Goulding SP; Creech AL; Serrano LR; Nasir G; Nasrullah Y; McGann CD; Velez D; Ting YS; Poran A; Rothenberg DA; Chhangawala S; Rubinsteyn A; Hammerbacher J; Gaynor RB; Fritsch EF; Greshock J; Oslund RC; Barthelme D; Addona TA; Arieta CM; Rooney MS
    Immunity; 2019 Oct; 51(4):766-779.e17. PubMed ID: 31495665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of immunogenic HLA class I and II neoantigens using surrogate immunopeptidomes.
    Tokita S; Fusagawa M; Matsumoto S; Mariya T; Umemoto M; Hirohashi Y; Hata F; Saito T; Kanaseki T; Torigoe T
    Sci Adv; 2024 Sep; 10(38):eado6491. PubMed ID: 39292790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mass Spectrometry-Based Immunopeptidomics of Peptides Presented on Human Leukocyte Antigen Proteins.
    ElAbd H; Franke A
    Methods Mol Biol; 2024; 2758():425-443. PubMed ID: 38549028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mapping the SARS-CoV-2 spike glycoprotein-derived peptidome presented by HLA class II on dendritic cells.
    Parker R; Partridge T; Wormald C; Kawahara R; Stalls V; Aggelakopoulou M; Parker J; Powell Doherty R; Ariosa Morejon Y; Lee E; Saunders K; Haynes BF; Acharya P; Thaysen-Andersen M; Borrow P; Ternette N
    Cell Rep; 2021 May; 35(8):109179. PubMed ID: 34004174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HLA Class II Presentation Is Specifically Altered at Elevated Temperatures in the B-Lymphoblastic Cell Line JY.
    Demmers LC; Wu W; Heck AJR
    Mol Cell Proteomics; 2021; 20():100089. PubMed ID: 33933681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disruption of HLA class II antigen presentation in Burkitt lymphoma: implication of a 47,000 MW acid labile protein in CD4+ T-cell recognition.
    God JM; Zhao D; Cameron CA; Amria S; Bethard JR; Haque A
    Immunology; 2014 Jul; 142(3):492-505. PubMed ID: 24628049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endogenous HLA class II epitopes that are immunogenic in vivo show distinct behavior toward HLA-DM and its natural inhibitor HLA-DO.
    Kremer AN; van der Meijden ED; Honders MW; Goeman JJ; Wiertz EJ; Falkenburg JH; Griffioen M
    Blood; 2012 Oct; 120(16):3246-55. PubMed ID: 22889757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunization with a peptide containing MHC class I and II epitopes derived from the tumor antigen SIM2 induces an effective CD4 and CD8 T-cell response.
    Kissick HT; Sanda MG; Dunn LK; Arredouani MS
    PLoS One; 2014; 9(4):e93231. PubMed ID: 24690990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV type 1 envelope glycoprotein 120 carboxy-terminal peptide-induced human T cell lines selectively suppress heterogeneous proliferative T cell responses to soluble antigens.
    Wilson SE; Habeshaw JA; Addawe MA; Hounsell EF; Oxford JS
    AIDS Res Hum Retroviruses; 1997 Oct; 13(15):1313-24. PubMed ID: 9339848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predicting HLA class II antigen presentation through integrated deep learning.
    Chen B; Khodadoust MS; Olsson N; Wagar LE; Fast E; Liu CL; Muftuoglu Y; Sworder BJ; Diehn M; Levy R; Davis MM; Elias JE; Altman RB; Alizadeh AA
    Nat Biotechnol; 2019 Nov; 37(11):1332-1343. PubMed ID: 31611695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biogenesis of HLA Ligand Presentation in Immune Cells Upon Activation Reveals Changes in Peptide Length Preference.
    Marino F; Semilietof A; Michaux J; Pak HS; Coukos G; Müller M; Bassani-Sternberg M
    Front Immunol; 2020; 11():1981. PubMed ID: 32983136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.